For treatment of Hepatitis C in India
Biocon announced the introduction of an advance novel therapy CIMIVIR-L for treatment of Hepatitis C in India. CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofobuvir 400 mg, which is an equivalent of the innovator product commercialised by Gilead Sciences in the US.Powered by Capital Market - Live News
